Please assess the completion status of the following clinical trial:

Trial Title: Preventing Sickle Cell Kidney Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pts with HbSS or SB0 thalassemia~* Hypertension from clinic BP readings (defined by NHLBI BP tables)~* Abnormal nocturnal dipping (systolic or diastolic) as defined by \<10% dip or abnormal nocturnal BP load (\>25% of sleep BP readings \>95th percentile as defined by AHA ABPM guidelines)~* Signed Informed Consent~Exclusion Criteria:~* Patient already on BP lowering medication~* Hyperkalemia~* Pregnancy

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 25 Years
- Healthy Volunteers: t

Study Arms:
- Standard Blood Pressure Management (Type: ACTIVE_COMPARATOR): Participants initiated on 25mg of losartan daily and randomized to lower in-clinic BP to \<95th percentile
- Experimental Blood Pressure Management (Type: EXPERIMENTAL): Participants initiated on 25mg of losartan daily and randomized to lower in-clinic BP to \<75th percentile

Based on this trial design, predict the completion outcome and termination type (if applicable).